Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor

Clinical Immunology and Immunopathology

Volumn 79, Issue 2, 1996, Pages 194-196

  Stricker, Raphael B ^a   Goldberg, Billi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030010279     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0067     Document Type: Article

References (14)

1. Gabrilove, J. L., Jakubowski, A., Fain, K., Grous, J., Scher, H., Sternberg, C., Yogoda, A., Clarkson, B., Bonilla, M. A., Oettgen, H. F., Alton, K., Boone, T., Altrock, B., Welte, K., and Souza, L., Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J. Clin. Invest. 82, 1454-1461, 1988.
2. Kerrigan, D. P., Castillo, A., Foucar, K., Townsend, K., and Meidhart, J., Peripheral blood morphologic changes after highdose antineoplastic chemotherapy and recombinant human granulocyte colony-stimulating factor administration. Am J. Clin. Pathol. 92, 280-285, 1989.
3. Hollingshead, L. M., and Goa, K. L., Recombinant granulocyte colony-stimulating factor (rG-CSF): A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42, 300-330, 1991.
4. Glaspy J. A., and Golde D. W., Granulocyte colony-stimulating factor (G-CSF): Preclinical and clinical studies. Semin. Oncol. 19, 386-394, 1992.
5. Miles, S. A., Mitsuyasu, R. T., Moren, J., Baldwin, G., Alton, N. K., Souza, L., and Glaspy, J. A., Combined therapy with recombinant granulocyte colony-stimulating fact of and erythropoietin decreases hematologic toxicity from zidovudine. Blood 77, 2109-2117, 1991.
6. Miles, S. A., The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies. Cancer Invest. 9, 229-238, 1991.
7. Miles, S. A., The use of hematopoietic growth factors in treating HIV infection. Curr. Opin. Hematol. 2, 227-233, 1995.
8. Garavelli, P. L., and Berti, P., Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia. AIDS 7, 589-590, 1993.
9. Stricker, R. B., Elswood, B. F., Goldberg, B., Dumlao, C., Van Elk, J., Henry, J., Winger, E. E., and Epstein, W. L., Clinical and immunologic evaluation of HIV-infected patients treated with dimtrochlorobenzene (DNCB). J. Am. Acad. Dermatol 31, 462-466, 1994.
10. Loughran, T. P., Clonal diseases of large granular lymphocytes. Blood 82, 1-14, 1993
11. Pantaleo, G., and Fauci, A. S., New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 13, 487-512, 1995.
12. Rowland-Jones, S., and McMichael, A., Cytotoxic T lymphocytes in HIV infection. Semin. Virol. 4, 83-94, 1993.
13. Scott-Algara, D., Vuillier, F., Cayota, A., and Dighiero, G., Natural killer (NK) cell activity during HIV infection: A decrease in NK activity is observed at the clonal level and is not restored after in vitro long-term culture of NK cells. Clin. Exp. Immunol. 90, 181-187, 1992.
14. Reale, M. A., Yun, Y., Strair, R. K., Flynn, S. D., and Cooper, D. L., Pseudoleukemia after granulocyte colony-stimulating factor therapy. South. Med. J. 88, 462-464, 1995.